A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
Completed · Phase 3 · NCT02998528
Conditions: Non Small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $7,342
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 505
About the trial
- Sponsor
- Bristol-Myers Squibb (with Ono Pharmaceutical Co., Ltd.)
- Tested
- Nivolumab (biological), Cisplatin (drug), Vinorelbine (drug), Gemcitabine (drug), Docetaxel (drug), Pemetrexed (drug), Carboplatin (drug), Paclitaxel (drug), Ipilimumab (biological)
- Dates
- Started 2017-03-04; completion 2024-12-06
- Results posted
- Yes
The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating resectable NSCLC. This study has multiple primary endpoints.
From ClinicalTrials.gov, last updated 2026-01-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $7,342 in research payments for this study in 2025 (4 payments).
Products named: Opdivo
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Makenzi C. Evangelist, M.D. Hematology & Oncology · Albany, NY
- James V. Uyeki, M.D. Medical Oncology · Austin, TX
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Texas Onco Southwest Fort Worth $3,193
- New York Oncology Hematology, PC $2,237
- Virginia Cancer Specialists, PC $1,912
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.